))
NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals
Manage episode 439224039 series 3594399
Treść dostarczona przez Soundcraft Media. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Soundcraft Media lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules.
In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages.
In episode 2 of NUKED we explore where the nukes come from, and how biotechs large and small get their hands on them.
With GlyTherix CEO Dr Brad Walsh and Telix Pharmaceuticals CEO Dr Chris Behrenbruch, we look at a potential new front in the US-China tariff war, the Russia question, and how an early stage biotech and one with a product in the market organises its nuclear material supplies.
Support the show
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
Rozdziały
1. NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals (00:00:00)
2. GlyTherix CEO Dr Brad Walsh (00:02:24)
3. Telix Pharmaceuticals CEO Dr Chris Behrenbruch (00:15:57)
16 odcinków
Udostępnij
